Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
14.76
+0.01 (0.07%)
At close: Nov 11, 2026, 4:00 PM EST
14.50
-0.26 (-1.76%)
After-hours: Nov 11, 2026, 4:34 PM EST
Company Description
Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases.
Its products in various stages of development include KP-104, a dual-complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) which is in Phase 2; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders.
The company is headquartered in Redwood City, California.
Jasper Therapeutics, Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Jeetinder Mahal |
Contact Details
Address: 2200 Bridge Pkwy, Suite #102 Redwood City, California 94065 United States | |
| Phone | 650-549-1400 |
| Website | jaspertx.com |
Stock Details
| Ticker Symbol | JSPR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1788028 |
| CUSIP Number | 471871301 |
| ISIN Number | US4718713013 |
| Employer ID | 84-2984849 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jeetinder Singh Mahal M.B.A. | President, Chief Executive Officer, Interim Chief Financial Officer and Director |
| Matthew E. Ros | Chief Operating Officer and Interim Corporate Secretary |
| Matthew Ford | Senior Vice President of Human Resources |
| Dr. Lisa Pitt Pharm.D. | Senior Vice President of Regulatory Affairs |
| Dr. Wenru Song M.D., Ph.D. | Executive Vice President and Head of Research & Development |
| Dr. Gregory F. Keenan M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 9, 2026 | 8-K | Current Report |
| Nov 4, 2026 | 8-K | Current Report |
| Oct 28, 2026 | SCHEDULE 13G | Filing |
| Oct 23, 2026 | SC TO-I/A | Filing |
| Oct 19, 2026 | DEF 14A | Other definitive proxy statements |
| Oct 15, 2026 | 8-K | Current Report |
| Oct 14, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Oct 9, 2026 | PRE 14A | Other preliminary proxy statements |
| Oct 7, 2026 | 8-K | Current Report |
| Oct 7, 2026 | SC TO-I | Filing |